ArticleNature communications2018
Overcoming EGFR
Abstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Comparing Real-Time PCR and Amplicon-Based NGS for RoutineDiagnostics (Basel, Switzerland) · 2026Article
- Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare ofThe journal of liquid biopsy · 2025Article
- Article
- Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma.Nature communications · 2025Article
- Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs.Medical oncology (Northwood, London, England) · 2025Review
- A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non-Small Cell Lung Cancer.Archiv der Pharmazie · 2025Review
- L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds.Proteins · 2025Article
- Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges.Biomedicines · 2025Review
- The changing treatment landscape of EGFR-mutant non-small-cell lung cancer.Nature reviews. Clinical oncology · 2025Review
- A structure-based tool to interpret the significance of kinase mutations in clinical next generation sequencing in cancer.Frontiers in oncology · 2025Article
- Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRBMC chemistry · 2024Article
- Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study.Biomedicines · 2024Article
- Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases.Scientific reports · 2024Article
- Traditional Chinese Medicine Formulae QY305 Reducing Cutaneous Adverse Reaction and Diarrhea by its Nanostructure.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.Frontiers in immunology · 2024Review
- Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms.F1000Research · 2024Article
- Characterization of Patients withOncoTargets and therapy · 2024Article
- Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.Targeted oncology · 2023Observational
- Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.Current oncology (Toronto, Ont.) · 2023Review
- Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Jana FassunkeInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Fabienne MüllerMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Marina KeulFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Sebastian MichelsLung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Marcel A DammertMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Anna SchmittCenter for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
Dennis PlenkerMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.ORCID http://orcid.org/0000-0003-3895-4064
Jonas LategahnFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Carina HeydtInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Johannes BrägelmannMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Hannah L TumbrinkMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Yannic AlberFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
Sebastian KleinInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Alena HeimsoethMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Ilona DahmenDepartment of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
Rieke N FischerLung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Matthias SchefflerLung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Michaela A IhleInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Vanessa PriesnerLung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Andreas H ScheelInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.ORCID http://orcid.org/0000-0003-0244-1646
Svenja WagenerInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Anna KronLung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
Konrad FrankSection Pneumology, Clinic III of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Katia GarbertMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Thorsten PersigehlInstitute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Michael PüskenInstitute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Stefan HanederInstitute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Bernhard SchaafHospital Dortmund gGmbH, Muensterstrasse 240, 44145, Dortmund, Germany.
Ernst RodermannOnkologie Rhein-Sieg, Schloßstraße 18, 53840, Troisdorf, Germany.
Walburga Engel-RiedelDepartment of Pneumology, Lung Hospital Cologne Merheim, City of Cologne Municipal Hospitals, Cologne, Germany.
Enriqueta FelipOncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Egbert F SmitThoracic Oncology Service, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Sabine Merkelbach-BruseInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
H Christian ReinhardtCenter for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.
Stefan M KastFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.ORCID http://orcid.org/0000-0001-7346-7064
Jürgen WolfLung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. juergen.wolf@uk-koeln.de.
Daniel RauhFaculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany. daniel.rauh@tu-dortmund.de.ORCID http://orcid.org/0000-0002-1970-7642
Reinhard BüttnerInstitute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. reinhard.buettner@uk-koeln.de.
Martin L SosMolecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. martin.sos@uni-koeln.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between selection of EGFR
Indexed as
AcrylamidesAniline CompoundsAnimalsCell Line, TumorDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansIndolesKineticsMiceMice, NudeMutationNIH 3T3 CellsPiperazinesAcrylamidesAniline CompoundsErbB ReceptorsIndolesosimertinibPiperazinesProtein Kinase InhibitorsPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.